Study of TNX-801 Vaccine Against Mpox and Smallpox
Author Information
Author(s): Trefry Stephanie V., Awasthi Mayanka, Raney Christy N., Cregger Amy L., Gonzales Chase A., Layton Brittney L., Enamorado Robert N., Martinez Nelson A., Gohegan Deborah S., Masoud-Bahnamiri Masoudeh, Cho Jennifer Y., Myscofski Dawn M., Moulaei Tinoush, Ziółkowska Natasza E., Goebel Scott J., Lederman Seth, Bavari Sina, Nasar Farooq
Primary Institution: Discovery and Translations Sciences, Tonix Pharmaceuticals, Frederick, Maryland, USA
Hypothesis
Is TNX-801 more attenuated than older vaccinia virus strains in both in vitro and in vivo models?
Conclusion
TNX-801 is significantly more attenuated than older vaccinia virus strains, showing no disease in murine models.
Supporting Evidence
- TNX-801 showed a small plaque phenotype in cell cultures.
- TNX-801 had lower infectious titers compared to VACV strains.
- TNX-801 did not cause disease in immunocompromised mice.
Takeaway
The TNX-801 vaccine is safer than older vaccines and doesn't make mice sick, which is good for people.
Methodology
The study involved in vitro and in vivo experiments comparing TNX-801 with various vaccinia virus strains.
Potential Biases
Potential bias due to the involvement of co-inventors in the study.
Limitations
The study is preclinical and results may not fully translate to human responses.
Participant Demographics
The study used murine models, specifically immunocompromised mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website